Amylyx reports positive LUCIDITY Phase 3 data for avexitide, raises $545 million
Amylyx said its Phase 3 trial of avexitide in post-bariatric hypoglycemia hit its primary endpoint, keeping a planned FDA filing by the end of 2026 on track.
SEC filing (2)